Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of mitochondria disorders
3.2.1.2 Government initiatives and funding for rare disease research
3.2.1.3 Growing awareness for rare disease treatment
3.2.1.4 Advancements in diagnostic technologies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of effective disease-modifying treatments
3.2.2.2 Regulatory hurdles and challenges
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Kearns-Sayre syndrome (KSS)
5.3 Leigh syndrome
5.4 Mitochondrial DNA depletion syndrome (MDS)
5.5 Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS)
5.6 Other diseases
Chapter 6 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Diagnostic tests
6.2.1 Test
6.2.1.1 Genetic testing
6.2.1.2 Muscle biopsy
6.2.1.3 Blood tests
6.2.1.4 Imaging tests
6.2.1.5 Other tests
6.2.2 End-user
6.2.2.1 Hospitals
6.2.2.2 Specialty clinics
6.2.2.3 Diagnostic centers
6.2.2.4 Research institutes
6.3 Treatment
6.3.1 Nutritional support
6.3.1.1 Dietary supplements
6.3.1.2 Antioxidants
6.3.2 Physical therapy
6.3.3 Other treatments
Chapter 7 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Netherlands
7.3.7 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Rest of Latin America
7.6 Middle East and Africa
7.6.1 Saudi Arabia
7.6.2 South Africa
7.6.3 UAE
7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Abcam Limited
8.2 Abliva AB
8.3 Blueprint Genetics Oy.
8.4 Centogene N.V.
8.5 GeneDx, LLC
8.6 GenSight Biologics
8.7 Kaneka Corporation
8.8 Khondrion
8.9 Reata Pharmaceuticals
8.10 Stealth BioTherapeutics
